Literature DB >> 3681040

Microwave-induced hyperthermia and radiotherapy in human superficial tumours: clinical results with a comparative study of combined treatment versus radiotherapy alone.

C E Lindholm1, E Kjellen, P Nilsson, S Hertzman.   

Abstract

Eighty-five evaluable superficial recurrent malignant tumours, mainly adenocarcinomas (78 per cent), in 38 patients were treated with either combined local hyperthermia (41-45 degrees C for four sessions) and low dose radiotherapy (30.0 Gy) or the same low dose radiotherapy alone. The treatment was given for two weeks. Hyperthermia was induced externally with 2450 MHz or 915 MHz microwaves. Totally 57 tumours were given combined treatment with a complete and partial response rate of 46 and 30 per cent, respectively (duration 1-38 months). In 18 patients with 2-10 superficial tumours each, 56 tumours were used in a comparative study, comparing the effect of combined hyperthermia and low dose radiotherapy versus the same low dose radiotherapy alone, the patients acting as their own controls. The total response rates were 89 and 50 per cent, respectively, in the two treatment modality groups. The difference in response rates is significant (p = 0.0039) in favour of the combined treatment, and this is also found when comparing complete remissions only (p = 0.0027). Local pain and normal tissue reactions presented problems during and after 2450 MHz microwave-induced hyperthermia treatment, performed without a coupling water bag system. Introduction of 915 MHz microwave-induced hyperthermia with a coupling deionized water bag system and refinement of microwave applicators, as well as the temperature control system considerably reduced these problems.

Entities:  

Mesh:

Year:  1987        PMID: 3681040     DOI: 10.3109/02656738709140410

Source DB:  PubMed          Journal:  Int J Hyperthermia        ISSN: 0265-6736            Impact factor:   3.914


  8 in total

Review 1.  Hyperthermia in cancer therapy: where are we today and where are we going?

Authors:  R A Steeves
Journal:  Bull N Y Acad Med       Date:  1992 Mar-Apr

2.  Interstitial laser hyperthermia: a new approach to local destruction of tumours.

Authors:  A C Steger; W R Lees; K Walmsley; S G Bown
Journal:  BMJ       Date:  1989-08-05

3.  Hyperthermia Is Now Included in the NCCN Clinical Practice Guidelines for Breast Cancer Recurrences: An Analysis of Existing Data.

Authors:  Vassilis Kouloulias; Sotiria Triantopoulou; Nikolaos Uzunoglou; Kyriaki Pistevou-Gompaki; Alfred Barich; Anna Zygogianni; George Kyrgias; Dimitris Kardamakis; Dimitris Pectasidis; John Kouvaris
Journal:  Breast Care (Basel)       Date:  2015-04       Impact factor: 2.860

4.  Comparison of magnetic nanoparticle and microwave hyperthermia cancer treatment methodology and treatment effect in a rodent breast cancer model.

Authors:  Alicia A Petryk; Andrew J Giustini; Rachel E Gottesman; B Stuart Trembly; P Jack Hoopes
Journal:  Int J Hyperthermia       Date:  2013-12       Impact factor: 3.914

5.  Hyperthermia induced NFkappaB mediated apoptosis in normal human monocytes.

Authors:  Natarajan Aravindan; Karthigayan Shanmugasundaram; Mohan Natarajan
Journal:  Mol Cell Biochem       Date:  2009-02-15       Impact factor: 3.396

6.  Hyperthermia improves local tumour control in locally advanced breast cancer.

Authors:  G Wiedemann; O Mella; R S Coltart; B C Schem; O Dahl
Journal:  Klin Wochenschr       Date:  1988-10-17

7.  Experimental Investigation of Magnetic Nanoparticle-Enhanced Microwave Hyperthermia.

Authors:  Brogan T McWilliams; Hongwang Wang; Valerie J Binns; Sergio Curto; Stefan H Bossmann; Punit Prakash
Journal:  J Funct Biomater       Date:  2017-06-22

8.  A short time interval between radiotherapy and hyperthermia reduces in-field recurrence and mortality in women with advanced cervical cancer.

Authors:  Caspar M van Leeuwen; Arlene L Oei; Kenneth W T K Chin; Johannes Crezee; Arjan Bel; Anneke M Westermann; Marrije R Buist; Nicolaas A P Franken; Lukas J A Stalpers; H Petra Kok
Journal:  Radiat Oncol       Date:  2017-04-27       Impact factor: 3.481

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.